Navigation Links
HUYA Bioscience Int'l Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
Date:4/14/2008

and pharmaceutical properties that may translate into a superior clinical profile over other HDAC inhibitors currently marketed or in development.

About HDACs

HDAC inhibitors, a new class of cancer drugs, work by controlling how tightly DNA is wound around accessory proteins, histones. By deacetylating (removing an acetyl group from) histones, HDACs appear to promote tighter winding of DNA around histone proteins, which leads to reduced access by gene transcription factors. This results in decreased expression of proteins involved in cell differentiation, cell cycle arrest and apoptotic elimination of damaged cells -- all of which contribute to the development of cancer. HDAC inhibitors are able to restore expression of cancer suppressing genes in a highly selective manner. Treatment with HDAC inhibitors also leads, indirectly, to the suppression of angiogenesis factors, helping to choke off the blood supply to tumors.

Although significant preclinical and clinical activity has been observed with HDAC inhibitors, most of the compounds currently in development have characteristics which may limit their potential for clinical success or broad applicability. In contrast, benzamide class HDAC inhibitors, of which HBI-8000 is a third generation member, have exhibited greater target specificity and fewer serious side effects. In particular, they have the best potential for combination with existing anti-tumor agents.

HUYA's Integrated Co-development Model (ICM)

The global pharmaceutical industry faces a pressing need for new untapped sources of pre-clinical and clinical stage compounds for the drug development process. HUYA was one of the first companies to recognize China's potential to help meet this need through its burgeoning biotechnology industry and world-class talent pool. HUYA pioneered an innovative approach -- the HUYA Integrated Co-development Model -- for partnering with Chinese research institutions and pharmaceutical compa
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
3. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
4. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
5. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
6. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
7. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
8. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
9. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
10. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
11. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- International, well-known,scientific experts were surprised ... mg/day),data presented as "extremely promising."[1] More ... clinicians critically reviewed these data.,These experts ... lipid-modifying,treatments, fenofibrate and bezafibrate, in treating ... patients with metabolic syndrome,and type 2 ...
(Date:12/16/2009)... 16 RealMed has been ranked ... the 2009 Top 20 Best in ... report. RealMed is a dynamic revenue cycle ... processing between healthcare providers and all ... firm specializing in vendor performance measurement in ...
(Date:12/16/2009)... WALTHAM, Mass., Dec. 16 According to ... medical technology market intelligence, health care reforms in ... stent market in 2009, and will continue to ... new Asia Pacific Markets for Interventional Cardiology ... by the Chinese government will allow the Chinese ...
Breaking Medicine Technology:International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Drinking Weight Depression Linked in Young Women 3A Study 57563 1Drinking Weight Depression Linked in Young Women 3A Study 57563 2Childhood Stroke More Common Than Thought 57559 1Childhood Stroke More Common Than Thought 57559 2Childhood Stroke More Common Than Thought 57559 3Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations 57557 1Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations 57557 2Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations 57557 3
... Sept. 19 Women with postmenopausal,osteoporosis receiving ... in bone mineral density (BMD) to those,receiving ... new,study presented at the 29th Annual Meeting ... Research. The study, called MOTION (Monthly ...
... CHICAGO, Sept. 19 Targanta Therapeutics Corporation,today ... the in vitro,activity of its lead antibiotic ... against a variety of susceptible and resistant ... presented today at the 47th,Annual Interscience Conference ...
Other Medicine Technology:New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis 2New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis 3New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis 4Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 2Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 3Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 4Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria 5
(Date:12/16/2009)... shows, , , WEDNESDAY, Dec. 16 (HealthDay News) -- Average ... 78 years, a record high, federal health officials said ... to live to 80.4 years on average and men ... U.S. Centers for Disease Control and Prevention. , ... than their parents, life expectancy in the United States ...
(Date:12/16/2009)... 16 OrthoAccel Technologies, Inc., developers of ... acceleration device to enhance orthodontics, announced Alison Davies ... UK. Ms. Davies has spent the last ... dental industry, most recently for nine years as ... makers of Invisalign . ,, ...
(Date:12/16/2009)... A new software program developed by CareRise ... facilities to calculate their staffing needs as it relates ... allows inpatient healthcare facilities to calculate their mandatory nurse-to-patient ... and receive a daily report as to how it ... leader in risk management in the healthcare industry, has ...
(Date:12/16/2009)... MassMutual,s Retirement Services Division has announced ... platform in Q2 2010. The new platform will ... investment change materials in a variety of themes. ... from a menu of creative options to support ... population. The new RetireSmart participant engagement platform will ...
(Date:12/16/2009)... FRANCISCO, Dec. 16 Quantros, Inc., a ... professional services solutions for the healthcare industry, announces ... division. Quantros has named software industry veteran Michael ... Tulloch will work from the company,s new Marlborough, ... is a natural one," explains Tulloch. "Quantros has ...
Breaking Medicine News(10 mins):Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2
... Governance Joins RiskMetrics and Glass Lewis in Urging Stockholders ... Inc. (Nasdaq: LCAV ) announces that the ... RiskMetrics Group,s ISS Governance Services and Glass Lewis & ... retain the Company,s current management and Board of Directors ...
... 11 Universal Capital Management, Inc. (OTC ... development company that provides management and strategic ... pleased to announce that one of its ... Professional Healthcare Billing Services (PHB) located in ...
... Nausea and Vomiting (PONV)CORONA DEL MAR, Calif., March 11 ... patient,s oxygen status known on a beat-by-beat basis. Not ... say that all patients should have this monitor. No ... ASA Newsletter on their web site between 1983 and ...
... bystanders," platelets may actually play a more sinister role in organ ... ... (Vocus) March 11, 2009 -- Scientists at Children,s National Medical ... in patients suffering from sepsis: platelets. , , , , ,The ...
... Orthopedic research studies have concluded that inexpensive off-the-shelf ... arch pain due to over-pronation than costly custom-made ... savings for a large segment of the population. ... in partnership with Footlogics Australia, have designed a ...
... Dr. William Groff will perform a PPP laser procedure ... Check local listings for airtime. SANTA CLARA, Calif., March ... seller of laser, light-based and radio-frequency devices for surgical, ... laser will be featured on The Doctors national television ...
Other Medicine News:Health News:Three Leading Proxy Advisory Firms are Unanimous in Recommending LCA-Vision Stockholders Support the Current Board of Directors 2Health News:Three Leading Proxy Advisory Firms are Unanimous in Recommending LCA-Vision Stockholders Support the Current Board of Directors 3Health News:Three Leading Proxy Advisory Firms are Unanimous in Recommending LCA-Vision Stockholders Support the Current Board of Directors 4Health News:iVolution Medical Systems Acquires Professional Healthcare Billing Services 2Health News:iVolution Medical Systems Acquires Professional Healthcare Billing Services 3Health News:American Society of Anesthesiologists (ASA) - Myths About 'Never Ending Pursuit of Patient Safety and Satisfaction' Debunked 2Health News:Children's National Research Links Platelets to Sepsis-Related Organ Failure 2Health News:Children's National Research Links Platelets to Sepsis-Related Organ Failure 3Health News:Millions in Potential Health Care Savings: Prefab Orthotics Found More Effective 2Health News:Millions in Potential Health Care Savings: Prefab Orthotics Found More Effective 3Health News:Millions in Potential Health Care Savings: Prefab Orthotics Found More Effective 4Health News:Lumenis(R) UltraPulse CO2 Laser to be Featured on National Television with Live Pearly Penile Papule (PPP) Procedure 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: